Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 18;15(1):13477.
doi: 10.1038/s41598-025-95783-4.

The demographic characteristics and prognosis of acute myeloid leukemia with t(3;3)/inv(3) in the united states: a SEER-based study

Xianfeng Ouyang  1   2 , Xia Wu  3   4 , Su Hu  1   2 , Wei Jiang  1   2 , Ying Guo  1   2 , Yan Huang  5   6
Affiliations

The demographic characteristics and prognosis of acute myeloid leukemia with t(3;3)/inv(3) in the united states: a SEER-based study

Xianfeng Ouyang et al. Sci Rep. .

Abstract

Acute myeloid leukemia (AML) with t(3;3) (q21; q26.2) or inv(3) (q21; q26.2) is a rare subtype of acute myeloid leukemia with a poor prognosis. Research on the demographic characteristics and clinical outcomes of AML patients with t(3;3) (q21; q26.2) or inv(3) (q21; q26.2) is limited. All AML patients diagnosed with t(3;3) (q21; q26.2) or inv(3) (q21; q26.2) between 2000 and 2021 from SEER (Surveillance, Epidemiology, and End Results Program) database were included in this study. Survival analysis was performed using the Kaplan-Meier method. The log-rank test was used to analyze the significance of differences between overall survival (OS) and cancer-specific survival (CSS). Due to being a retrospective study, the limited amount of baseline characteristics available, and the missing information on treatments and recurrence, the provided dataset is not exactly representative for the US population. The median age of the total 90 AML patients with t(3;3) (q21; q26.2) or inv(3) (q21; q26.2) was 65(49-74) years old. Among them, 57.78% were married and non-Hispanic whites accounted for 74.44%. 84.44% of the patients received chemotherapy. The median OS was 8 months, and the median CSS was 10 months. The 5-year survival rate for OS was 15.29% (95%CI:7.98-24.78%), and 20.05% (95%CI:10.69-31.51%) for CSS. The OS and CSS of patients above 60 years were inferior to those of patients under 60 years. Single (never-married) patients had better OS and CSS than those with other marital status. Age and marital status at diagnosis were independent influencing factors for OS and CSS based on the multivariate COX regression analysis. AML with t(3;3) (q21; q26.2) or inv(3) (q21; q26.2) mostly occurs in adults and has poor clinical outcomes with worse OS and CSS, especially in the elderly.

Keywords: GATA2; MECOM; Acute myeloid leukemia; Acute myeloid leukemia with t(3; 3)/inv(3); Cancer-specific survival; Overall survival.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate: Not Applicable. Consent for publication: Not Applicable. Competing interests: The authors declare no competing interests. Conflict of interest: All authors declare that they have no conflict of interests.

Figures

Fig. 1
Fig. 1
Age distribution based on gender for AML patients with t(3;3)/inv(3) (n = 90). The age distribution state of female and male AML patients with t(3;3)/inv(3).
Fig. 2
Fig. 2
The OS and CSS of total AML patients with t(3;3) /inv(3) (n = 90). A. The OS of all patients. B. The CSS of all patients.
Fig. 3
Fig. 3
The OS and CSS based on age. A. The OS based on age. B The CSS based on age.
Fig. 4
Fig. 4
The OS and CSS based on sex. A. The OS based on sex. B. The CSS based on sex.
Fig. 5
Fig. 5
The OS and CSS based on year of diagnosis. A. The OS based on year of diagnosis. B. The CSS based on year of diagnosis.
Fig. 6
Fig. 6
The OS and CSS based on marital status. A. The OS based on marital status. B. The CSS based on marital status.
Fig. 7
Fig. 7
The OS and CSS based on chemotherapy. A. The OS based on chemotherapy. B The CSS based on chemotherapy. “Yes” representative being received chemotherapy and “No/Unknown” representative not or unknown received chemotherapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. JULIUSSON, G. & ANTUNOVIC, P. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry [J]. Blood113 (18), 4179–4187 (2009). - PubMed
    1. DöHNER, H. & WEISDORF D J, BLOOMFIELD, C. D. Acute myeloid leukemia [J]. N Engl. J. Med.373 (12), 1136–1152 (2015). - PubMed
    1. NEWELL L F COOK R J. Advances in acute myeloid leukemia [J]. BMJ375, n2026 (2021). - PubMed
    1. SASAKI, K. et al. De Novo acute myeloid leukemia: A population-based study of outcome in the united States based on the surveillance, epidemiology, and end results (SEER) database, 1980 to 2017 [J]. Cancer127 (12), 2049–2061 (2021). - PMC - PubMed
    1. GRIMWADE, D. et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the united Kingdom medical research Council trials [J]. Blood116 (3), 354–365 (2010). - PubMed

LinkOut - more resources